Smart Program Design Through a Common Information Model.

导出 LinkOut

翻译打印收藏纠错

作者： Laszlo,Vasko ^[1] ; Mats,Sundgren ^[2] ; Peter,Bachmann ^[3] ; Kathe,Balinski ^[4] ; Norbert,Bleich ^[3] ; Taru,Blom ^[5] ; Hans,Eriksson ^[6] ; Robert,Ferendo ^[7] ; Kerstin,Forsberg ^[2] ; Diane,King ^[7] ; Alphonse,Mordiva ^[8] ; Johann,Proeve ^[9] ; Leslie,Thomas ^[7] ; Emma,Witch ^[10] ; Martin,Simán ^[2]

作者单位： 1 AstraZeneca R&D, Wilmington, DE, USA. ^[1] 2 AstraZeneca R&D, Molndal, Sweden. ^[2] 3 Roche, Basel, Switzerland. ^[3] 9 ImClone Systems, Bridgewater, NJ, USA. ^[4] 5 Orion Pharma, Turku, Finland. ^[5] 6 Lundbeck, Copenhagen, Denmark. ^[6] 4 Eli Lilly & Company, Indianapolis, IN, USA. ^[7] 7 Merck Serono, Darmstadt, Germany. ^[8] 8 Bayer Healthcare, Leverkusen, Germany. ^[9] 10 AstraZeneca R&D, Alderley Park, UK. ^[10]

关键词 Best practice Clinical program and trial design Collaboration Information model Success factors

DOI 10.1177/2168479014539158

PMID 30222460

发布时间 2020-01-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览13

Therapeutic innovation & regulatory science

2015年49卷1期

116-125页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Smart Program Design Through a Common Information Model.

Therapeutic innovation & regulatory science

相似文献

Therapeutic innovation & regulatory science

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Smart Program Design Through a Common Information Model.

Therapeutic innovation & regulatory science

相似文献

Therapeutic innovation & regulatory science

相关期刊

检索历史清除